Corrie Gallant-Behm

Corrie Gallant-Behm is a seasoned research professional with extensive experience in the biotechnology and therapeutic development sectors. Currently serving as Senior Director of Research at Atalanta Therapeutics since January 2020, Corrie previously held roles at miRagen Therapeutics, Inc. as Associate Director and Research Scientist, leading preclinical development of miR-29-based therapeutics. Academic background includes postdoctoral fellowships at Northwestern University and the University of Calgary, where Corrie focused on cancer biology, tissue repair, and regeneration. Corrie's education includes a PhD in Molecular Biology and Genetics and a master's degree in Quality Assurance and Regulatory Sciences from Northwestern University, complemented by various teaching and mentoring roles throughout the career.